Vol.97 No.5 contentsPRACTICA OTO-RHINO-LARYNGOLOGICA
Vol. 97 No. 5 May 2004
Efficacy of
Onon® (pranlukast hydrate) for the
Improvement of Quality of Life in Patients with
Allergic Rhinitis
Mitsuyoshi Nagura, Satoshi Iwasaki,Yasuyuki Hashimoto, Takahiro Watanabe,
Satoru Takebayashi, Hiroyuki Mineta and Tomoyuki Hoshino
(Hamamatsu University School of Medicine)
Keisuke Araki
(Shizuoka Saiseikai Hospital)
The aim of this study was to evaluate the effects of novel leukotriene antagonist, pranlukast hydrate on improvement of quality of life (QOL) as well as reduction of clinical symptoms in patients with allergic rhinitis.
Fifty patients with perennial and/or seasonal allergic rhinitis were administered 450 mg pranlukast hydrate daily for at least 4 weeks. The severity of clinical symptoms and QOL were assessed before and after treatment.
After a 4-week period of treatment, the QOL score significantly improved from 2.1±1.5 to 1.2±1.7 (P＜0.0001). In addition, the treatment itself did not affect the QOL of the patients. The severity of symptoms was also significantly reduced (P＜0.001). The improvement rates were 66.0％ (sneezing), 72.0％ (rhinorrea), and 82.0％ (nasal obstruction).
In conclusion, pranlukast hydrate improves QOL and reduces symptoms in patients with allergic rhinitis.
Key words : pranlukast hydrate, quality of life, allergic rhinitis, leukotriene antagonist, nasal obstruction